CIK 0001615219
- Non-accelerated filer
- Smaller reporting company
Decoy Therapeutics Inc.
Sign in to watch- Ticker
- DCOY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 465087339
- Phone
- +1 346-772-0346
- Business address
- 2450 HOLCOMBE BLVD, SUITE J-608, HOUSTON, TX, 77021
- Former names
- Salarius Pharmaceuticals, Inc., Flex Pharma, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 44 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-07-26 | Stacy Michelle Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2017-07-26 | RANDLE STUART A Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2017-07-26 | McVicar William K. President and CEO | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2017-07-26 | MacKinnon Roderick Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2017-07-26 | KOZIN MARC D Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2017-07-26 | HUTT PETER BARTON Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2017-07-26 | CAPELLO JEFFREY D Director | Grant or award · Stock Option (right to buy) | +12,000 | 12,000 | ||
| 2017-05-26 | McVicar William K. President, R&D | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2017-01-18 | Woo Elizabeth SVP, Investor Relations | Grant or award · Stock Option (right to buy) | +47,000 | 47,000 | ||
| 2017-01-18 | Wessel Thomas Chief Medical Officer | Grant or award · Stock Option (right to buy) | +85,000 | 85,000 | ||
| 2017-01-18 | McCabe John P. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +67,000 | 67,000 | ||
| 2017-01-18 | Lindemann Katharine Chief Operating Officer | Grant or award · Stock Option (right to buy) | +77,000 | 77,000 | ||
| 2017-01-18 | Hadfield Robert General Counsel & Secretary | Grant or award · Stock Option (right to buy) | +57,000 | 57,000 | ||
| 2016-11-08 | Westphal Christoph H President and CEO | Purchase | +7,000 | $7.31 | $51K | 3,941,118 |
| 2016-11-07 | Westphal Christoph H President and CEO | Purchase | +8,870 | $5.70 | $51K | 3,934,118 |
| 2016-11-07 | McCabe John P. VP of Finance & Treasurer | Purchase | +1,650 | $6.01 | $10K | 1,650 |
| 2016-06-23 | Westphal Christoph H President and CEO | Purchase | +2,700 | $11.28 | $30K | 3,212,861 |
| 2016-06-22 | Westphal Christoph H President and CEO | Purchase | +2,900 | $11.03 | $32K | 3,210,161 |
| 2016-06-21 | Westphal Christoph H President and CEO | Purchase | +2,800 | $11.07 | $31K | 3,207,261 |
| 2016-06-20 | Westphal Christoph H President and CEO | Purchase | +3,000 | $11.37 | $34K | 3,204,461 |
Page 8 of 12 · 229 trades